Peter H. O'Donnell to Disease-Free Survival
This is a "connection" page, showing publications Peter H. O'Donnell has written about Disease-Free Survival.
Connection Strength
0.178
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
Score: 0.040
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
Score: 0.040
-
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492.
Score: 0.031
-
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep 14; 3(9):e172411.
Score: 0.031
-
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
Score: 0.025
-
Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001 Dec 01; 19(23):4314-21.
Score: 0.010